-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Chemed, Lowers Price Target to $580

Benzinga·07/31/2025 12:47:58
Listen to the news
Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and lowers the price target from $650 to $580.